These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 22310795)

  • 1. Clinical features of acute viral hepatitis B in Korea: a multi-center study.
    Choi HJ; Ko SY; Choe WH; Seo YS; Kim JH; Byun KS; Kim YS; Kim SU; Baik SK; Cheong JY; Kim TY; Kwon OS; Kim JH; Lee CH; Kwon SY
    Korean J Hepatol; 2011 Dec; 17(4):307-12. PubMed ID: 22310795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application strategies of serum HBV DNA detection in HBV infection patients: A retrospective study of 5611 specimens.
    Liu C; Wu W; Shang S; Huang E; Xun Z; Lin J; Chen T; Yang B; Chen J; Ou Q
    J Med Virol; 2019 Feb; 91(2):249-257. PubMed ID: 30011350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of switching from treatment with nucleos(t)ide analogs to pegylated interferon α-2a on virological and serological responses in chronic hepatitis B patients.
    He LT; Ye XG; Zhou XY
    World J Gastroenterol; 2016 Dec; 22(46):10210-10218. PubMed ID: 28028369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. N-acetyl cysteine therapy in acute viral hepatitis.
    Gunduz H; Karabay O; Tamer A; Ozaras R; Mert A; Tabak OF
    World J Gastroenterol; 2003 Dec; 9(12):2698-700. PubMed ID: 14669316
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of 48-week response of treatment-naive chronic hepatitis B patients to 0.5 mg/day entecavir.
    Kölgelier S; Aktuğ Demir N; Özçimen S; Sümer Ş
    Turk J Med Sci; 2014; 44(2):283-7. PubMed ID: 25536738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Failure of therapeutic vaccination using hepatitis B surface antigen vaccine in the immunotolerant phase of children with chronic hepatitis B infection.
    Dikici B; Bosnak M; Ucmak H; Dagli A; Ece A; Haspolat K
    J Gastroenterol Hepatol; 2003 Feb; 18(2):218-22. PubMed ID: 12542609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Can HBsAg levels guide to differentiate inactive HBsAg carriers from HBeAg negative chronic B hepatitis?].
    Sayan M; Mutlu B; Erdoğan S; Meriç M; Willke A
    Mikrobiyol Bul; 2007 Jan; 41(1):87-93. PubMed ID: 17427556
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Establishment of a simple model for hepatitis B virus infection status based on trait marker from quantitative measurement of serum markers.
    Ningyu Z; Ying Z; Hui L
    J Med Virol; 2015 Jun; 87(6):1008-12. PubMed ID: 25716104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized controlled trial of lamivudine to treat acute hepatitis B.
    Kumar M; Satapathy S; Monga R; Das K; Hissar S; Pande C; Sharma BC; Sarin SK
    Hepatology; 2007 Jan; 45(1):97-101. PubMed ID: 17187417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of HBeAg/anti-HBe, ALT levels, and HBV DNA PCR results in HBsAg-positive patients.
    Ljunggren KK; Nordenfelt E; Kidd A
    J Med Virol; 1993 Apr; 39(4):297-302. PubMed ID: 8492102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy.
    Chaung KT; Ha NB; Trinh HN; Garcia RT; Nguyen HA; Nguyen KK; Garcia G; Ahmed A; Keeffe EB; Nguyen MH
    J Clin Gastroenterol; 2012; 46(10):865-70. PubMed ID: 22941429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Change of HBV DNA level as a predictor of HBeAg loss after lamivudine treatment].
    Jung JK; Lee CH; Kim EY; Jung JT; Choi JH; Han JM; Jin MI; Cho JY; Kim BS; Shin IH
    Korean J Hepatol; 2007 Dec; 13(4):513-20. PubMed ID: 18159149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluctuations in viremia, aminotransferases and IgM antibody to hepatitis B core antigen in chronic hepatitis B patients with disease exacerbations.
    Mels GC; Bellati G; Leandro G; Brunetto MR; Vicari O; Borzio M; Piantino P; Fornaciari G; Scudeller G; Angeli G
    Liver; 1994 Aug; 14(4):175-81. PubMed ID: 7968277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NIH consensus development statement on management of hepatitis B.
    Belongia EA; Costa J; Gareen IF; Grem JL; Inadomi JM; Kern ER; McHugh JA; Petersen GM; Rein MF; Sorrell MF; Strader DB; Trotter HT
    NIH Consens State Sci Statements; 2008 Oct 22-24; 25(2):1-29. PubMed ID: 18949020
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial.
    Bazinet M; Pântea V; Cebotarescu V; Cojuhari L; Jimbei P; Albrecht J; Schmid P; Le Gal F; Gordien E; Krawczyk A; Mijočević H; Karimzadeh H; Roggendorf M; Vaillant A
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):877-889. PubMed ID: 28964701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative hepatitis B surface antigen titres in Chinese chronic hepatitis B patients over 4 years of entecavir treatment.
    Chen EQ; Wang TT; Bai L; Tao CM; Liang T; Liu C; Liao J; Tang H
    Antivir Ther; 2013; 18(8):955-65. PubMed ID: 23639885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment efficacy of clevudine, entecavir and lamivudine in treatment-naive patients with HBeAg-positive chronic hepatitis B].
    Bae SH; Baek YH; Lee SW; Han SY
    Korean J Gastroenterol; 2010 Dec; 56(6):365-72. PubMed ID: 21173560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
    Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
    PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
    Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
    Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.